Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 15/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.39 |
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337224 | 0.86 | CPN1 (0.40) | CPN1CPB2DPP4DPP7DPP8 | |
| SCHEMBL3465079 | 0.81 | CPN1 (0.43) | CPN1CPB2DPP4DPP7FAP | |
| SCHEMBL24021438 | 0.80 | JAK3 (0.42) | — | |
| SCHEMBL24449568 | 0.79 | CPN1 (0.42) | CPN1CPB2DPP4DPP7FAP | |
| SCHEMBL1008330 | 0.79 | CA1 (0.40) | CPN1CPB2DPP4DPP7PREP | |
| SCHEMBL24777627 | 0.79 | CA1 (0.43) | CPN1CPB2 | |
| SCHEMBL23827142 | 0.78 | DPP4 (0.40) | CPN1CPB2DPP4DPP7FAP | |
| SCHEMBL23827144 | 0.78 | DPP4 (0.40) | CPN1CPB2DPP4DPP7FAP | |
| SCHEMBL16345047 | 0.78 | ALDH1A1 (0.50) | DPP4PREP | |
| SCHEMBL18793692 | 0.78 | ALDH1A1 (0.50) | DPP4PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2194058-B1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-1946725-B | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORP | 2011-02-23 | — | — | CN | disclosed |
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1720882-A2 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7119200-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060128725-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-06-15 | — | — | US | disclosed |
| WO-2005077954-A2 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1537116-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004022561-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128725-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CPN1 2777/4885CPB2 3023/4885DPP4 1785/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | CPN1 802/4885CPB2 990/4885DPP4 379/4885 |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDK5 | CPN1 2515/4885CPB2 3180/4885DPP4 1498/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CPN1 2777/4885CPB2 3023/4885DPP4 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.